UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

—————————

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

—————————

For the month of March 2007

 

Commission File Number: 001-31368

 

SANOFI-AVENTIS

(Translation of registrant’s name into English)

 

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

 

        Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x
Form 40-F o

        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

        Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

       Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o
No x

       If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________ 

 

 

 

 

 

 

 


In March 2007, sanofi-aventis issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

 

Exhibit List

 

Exhibit No.

Description

 

Exhibit 99.1

Press release dated March 28, 2007 “Sanofi-aventis and Oxford BioMedica Enter Global Licensing Agreement to Develop and Commercialise TroVax® For Cancer”

 

 

 

 

 

 

 

2

 

 

 


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: March 28, 2007

SANOFI-AVENTIS

   
  By:  /s/ Patricia Kodyra        
Name: Patricia Kodyra
    Title: Associate Vice President
Financial and Securities Law

 

 

 

 

 

 

 

 

 

 

3

 

 

 


Exhibit Index

 

Exhibit No.

Description

 

Exhibit 99.1

Press release dated March 28, 2007 “Sanofi-aventis and Oxford BioMedica Enter Global Licensing Agreement to Develop and Commercialise TroVax® For Cancer”

 

 

 

 

 

 

 

 

 

 

 

 

4